(Total Views: 747)
Posted On: 06/25/2025 12:26:44 AM
Post# of 154603
PD-L1 journey clarity....
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov ID NCT04504942
Quest
___
Compassionate Use Study of Leronlimab in Breast Cancer
ClinicalTrials.gov ID NCT04313075
No CRO mention
No location
___
Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
ClinicalTrials.gov ID NCT03838367
Outcome Measure:
Correlation between CCR5 expression (CTCs, CAMLs) and PD- L1 expression.
Amarex Clinical Research
___
Dr. J = had basket trial data
Amarex = PD-L1 compiled data
July 2024 received Amarex data.
Sept. 9th, 2024: "We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors."
2022, Scott Kelly said Cytodyn signed with a major academic to run synergies with LL & immune checkpoint inhibitors.
Trial NCT03838367 compiled PD-L1 data.
May 13, 2025:
"...and received treatment with any ICI remain alive today."
___
From July, to by Sept. 2024, they verified the Amarex data, was the last piece of a multi-year PD-L1 puzzle.
Amarex was the last piece, not the start of validating mTNBC data & fully going forward with new trials & follow-ups on Ladies of Leronlimab
Feb. 2025 news was ESMO @ May 15th, 2025.
New MOA of cold/hot tumors 2 days before ESMO
Due to easily by ESMO, Cytodyn could have already been in talks with multiple parties for almost 10 months or so.
From companies to the EU & etc...
Gives reasoning why even our lawyer went to ESMO.
Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.gov ID NCT04504942
Quest
___
Compassionate Use Study of Leronlimab in Breast Cancer
ClinicalTrials.gov ID NCT04313075
No CRO mention
No location
___
Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
ClinicalTrials.gov ID NCT03838367
Outcome Measure:
Correlation between CCR5 expression (CTCs, CAMLs) and PD- L1 expression.
Amarex Clinical Research
___
Dr. J = had basket trial data
Amarex = PD-L1 compiled data
July 2024 received Amarex data.
Sept. 9th, 2024: "We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors."
2022, Scott Kelly said Cytodyn signed with a major academic to run synergies with LL & immune checkpoint inhibitors.
Trial NCT03838367 compiled PD-L1 data.
May 13, 2025:
"...and received treatment with any ICI remain alive today."
___
From July, to by Sept. 2024, they verified the Amarex data, was the last piece of a multi-year PD-L1 puzzle.
Amarex was the last piece, not the start of validating mTNBC data & fully going forward with new trials & follow-ups on Ladies of Leronlimab
Feb. 2025 news was ESMO @ May 15th, 2025.
New MOA of cold/hot tumors 2 days before ESMO
Due to easily by ESMO, Cytodyn could have already been in talks with multiple parties for almost 10 months or so.
From companies to the EU & etc...
Gives reasoning why even our lawyer went to ESMO.
(3)
(0)
